HUP0401534A2 - Módosított humán IX. faktor - Google Patents

Módosított humán IX. faktor

Info

Publication number
HUP0401534A2
HUP0401534A2 HU0401534A HUP0401534A HUP0401534A2 HU P0401534 A2 HUP0401534 A2 HU P0401534A2 HU 0401534 A HU0401534 A HU 0401534A HU P0401534 A HUP0401534 A HU P0401534A HU P0401534 A2 HUP0401534 A2 HU P0401534A2
Authority
HU
Hungary
Prior art keywords
modified
subject
polypeptides
factor
humans
Prior art date
Application number
HU0401534A
Other languages
English (en)
Inventor
Francis J. Carr
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0401534A2 publication Critical patent/HUP0401534A2/hu
Publication of HUP0401534A3 publication Critical patent/HUP0401534A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány tárgyát olyan polipeptidek képezik, amelyek - elsősorbanterápiás célból - speciálisan embereknek adagolhatók. A találmányszerinti polipeptidek módosított polipeptidek, mely módosításeredményeként a polipeptid - embereknek történő adagolása esetén -kevésbé hajlamos immunreakció kiváltására. Közelebbről, a találmánytárgyát humán IX. faktor módosított változatai képezik, mely IX.faktor proteinváltozatok in vivo alkalmazáskor lényegében nemimmunogének vagy kevésbé immunogének, mint a megfelelő, módosításnélküli alakjuk. A találmány tárgyát képezik továbbá a találmányszerinti módosított IX. faktor molekulákat kódoló DNS-ek, a találmányszerinti módosított IX. faktor molekulákat tartalmazó gyógyászatikészítmények, valamint eljárások a módosított IX. faktor molekulákelőállítására. Ó
HU0401534A 2001-09-04 2002-08-30 Modified factor ix HUP0401534A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01121154 2001-09-04
PCT/EP2002/009717 WO2003020764A2 (en) 2001-09-04 2002-08-30 Modified factor ix

Publications (2)

Publication Number Publication Date
HUP0401534A2 true HUP0401534A2 (hu) 2004-11-29
HUP0401534A3 HUP0401534A3 (en) 2006-01-30

Family

ID=8178534

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401534A HUP0401534A3 (en) 2001-09-04 2002-08-30 Modified factor ix

Country Status (13)

Country Link
US (1) US20040254106A1 (hu)
EP (1) EP1427820A2 (hu)
JP (1) JP2005501547A (hu)
KR (1) KR20040039328A (hu)
CN (1) CN1547608A (hu)
BR (1) BR0212035A (hu)
CA (1) CA2457429A1 (hu)
HU (1) HUP0401534A3 (hu)
MX (1) MXPA04001982A (hu)
PL (1) PL369065A1 (hu)
RU (1) RU2004110239A (hu)
WO (1) WO2003020764A2 (hu)
ZA (1) ZA200402606B (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2084274A2 (en) 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
US8304382B2 (en) * 2006-07-21 2012-11-06 Cristalia Productos Quimicos Farmaceuticos Ltda. Anti-inflammatory and anti-allergic cyclic peptides
EP2167528B1 (en) 2007-06-21 2018-01-10 Angelica Therapeutics, INC. Modified toxins
CA2702363A1 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
US8470314B2 (en) 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
RU2010146387A (ru) * 2008-04-16 2012-05-27 БАЙЕР ХЕЛСКЕР ЛЛСи (US) Модифицированные полипептиды фактора ix и их применение
HUE061345T2 (hu) 2008-09-15 2023-06-28 Uniqure Biopharma B V IX-es faktor polipeptid mutáns, alkalmazásai és eljárás elõállítására
EP2590668A4 (en) 2010-07-09 2014-04-02 Biogen Idec Hemophilia Inc FACTOR IX POLYPEPTIDES AND METHOD OF USE THEREOF
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
PT2956477T (pt) 2013-02-15 2021-02-05 Bioverativ Therapeutics Inc Gene do fator viii otimizado
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
SG11201607642RA (en) 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
DK3411478T3 (da) 2016-02-01 2022-09-12 Bioverativ Therapeutics Inc Optimerede faktor viii-gener
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
MX2019009063A (es) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.
CA3072334A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
WO2019067766A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
WO2019195055A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
KR20210042128A (ko) 2018-08-09 2021-04-16 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
WO2020215010A1 (en) 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Compositions of exosomes and aav
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
EP1724282B1 (en) * 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
ES2278463T3 (es) * 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.

Also Published As

Publication number Publication date
RU2004110239A (ru) 2005-10-20
CN1547608A (zh) 2004-11-17
MXPA04001982A (es) 2004-06-07
JP2005501547A (ja) 2005-01-20
ZA200402606B (en) 2004-12-14
HUP0401534A3 (en) 2006-01-30
US20040254106A1 (en) 2004-12-16
EP1427820A2 (en) 2004-06-16
WO2003020764A2 (en) 2003-03-13
CA2457429A1 (en) 2003-03-13
KR20040039328A (ko) 2004-05-10
PL369065A1 (en) 2005-04-18
BR0212035A (pt) 2004-08-03
WO2003020764A3 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
HUP0401534A2 (hu) Módosított humán IX. faktor
HUP0400700A2 (hu) Csökkentett immunogenitású, módosított humán agyi eredetű neutróf faktor (BDNF)
CY1119369T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
HK1112367A1 (en) Survivin peptide vaccine
UA105210C2 (ru) Противораковая вакцина и ее применение
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
YU72901A (sh) Preparati za primenu u terapiji i dijagnozi raka pluća
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
HUP0400231A2 (hu) Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
TW200806289A (en) Sustained-release formulation of zonisamide
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
HK1068606A1 (en) Novel aminobenzoephenones
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
HUP0402071A2 (hu) Csökkentett immunogenitású, módosított leptin
DE60113805D1 (de) Intratumorale verabreichung nackter il-12 codierender nukleinsäuremoleküle
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
HUP0400698A2 (hu) Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA)
HUP0303430A2 (hu) Csökkentett immunogenitású, módosított protamin
HUP0402334A2 (hu) Módosított humán növekedési hormon

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished